Evaxion A/S (EVAX) chief scientific officer lists warrant and share holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Evaxion A/S filed an initial ownership report for its Chief Scientific Officer, detailing holdings of warrants and ordinary shares of Evaxion A/S. The filing shows direct ownership of 36,765 ordinary shares and multiple warrant series over additional ordinary shares at various exercise prices and expirations.
These warrants cover amounts such as 36,765 underlying shares at an exercise price of $0.74 expiring on December 21, 2026, and other grants with exercise prices including $0.10, $0.40, $0.75, $2.23, and $5.38 expiring on dates through 2036. One warrant position stems from a private placement that closed on December 21, 2023, and certain grants vest at a rate of 1/36 per month over 36 months from their initial exercise dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Evaxion A/S
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 36,765 shares (Direct);
Ordinary Shares — 36,765 shares (Direct)
Footnotes (1)
- Warrants pursuant to private placement that closed 12/21/2023. Vesting is 1/36 per month over 36 months from the initial exercise date indicated.
FAQ
What does Evaxion A/S (EVAX) report in this Form 3 filing?
Evaxion A/S reports its Chief Scientific Officer’s initial ownership in company securities. The filing lists directly held ordinary shares and multiple warrant grants, each with specific exercise prices, expiration dates, and vesting terms, providing a baseline view of this insider’s equity-linked position.
What warrant positions are disclosed for Evaxion A/S (EVAX) in this Form 3?
The filing lists several warrant series over Evaxion A/S ordinary shares. Examples include 36,765 underlying shares at $0.74 per share expiring in December 2026 and other warrants with $0.10, $0.40, $0.75, $2.23, and $5.38 exercise prices expiring through 2036.
Is any Evaxion A/S warrant position tied to a private placement?
Yes. A footnote states that one set of warrants was issued pursuant to a private placement that closed on December 21, 2023. This clarifies that those particular warrants originated from a financing transaction, rather than from standard employee or officer compensation grants.
How do vesting terms work for certain Evaxion A/S warrants in this Form 3?
A footnote explains that some warrants vest at 1/36 per month over 36 months from the initial exercise date listed. This means the right to exercise these warrants becomes available gradually, aligning vesting with the specified multi-year schedule.
Does the Evaxion A/S Form 3 show any insider buying or selling activity?
The Form 3 presents holding entries rather than new purchases or sales. It establishes the Chief Scientific Officer’s existing ownership of ordinary shares and warrants, without recording open-market buy or sell transactions in the disclosed summary data.